Temat: Koronawirus SARS-CoV-2 (COVID-19)

The onset of chronic, debilitating symptoms following SARS-CoV-2 vaccination is thought to constitute a novel disease entity, for which the term post-acute COVID-19 vaccination syndrome (PACVS) has recently been suggested [1]. The symptoms reported by PACVS-affected persons start shortly after SARS-CoV-2 vaccination, continue in episodes over several months, and severely compromise the quality of life. A systematic survey of the clinical features of PACVS has yet to be carried out. However, published case reports [1] indicate that PACVS differs from the usual adverse effects of SARS-CoV-2 vaccination [2,3,4,5]. The symptoms most frequently reported in the context of PACVS encompass impaired well-being (exhaustion, malaise, chronic fatigue), cardiovascular disturbances (orthostatic intolerance, tachycardia, palpitations), peripheral neuropathy (dysesthesia, hypesthesia), central nervous system dysfunction (lack of concentration, brain fog, cognitive deficits, sleep disorders), muscular dysfunction (myalgia, weakness, fibrillations), and gastro-intestinal afflictions (nausea, strong weight changes). In summary, PACVS presents a phenotype of acquired autonomous dysfunction that overlaps with various established multisystemic dysautonomia syndromes such as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) [6,7], postural orthostatic tachycardia syndrome (POTS) [8], fibromyalgia/chronic pain syndrome [9], small fiber neuropathy (SFN) [10] and mast cell activation syndrome (MCAS) [11]. Interestingly, symptoms similarly conforming to ME/CFS and POTS have been observed following vaccinations against human papillomavirus [12,13,14,15,16] and hepatitis B virus [17].

The fraction of vaccinated persons suffering from PACVS is unknown. Current estimates assume an incidence of 0.02%, amounting to 40,000 affected persons in Germany alone.

From the RCTs in children aged 6 months to 15(17) years, neither of the mRNA vaccines had a beneficial
effect on overall health, assessed as the incidence of SAEs, Severe AEs, RTIs, and other organ-specific
diseases.
mRNA vaccines were not associated with an increased risk of SAEs, but the risk of Severe AEs was
more than 3.5-fold higher in the older children. In younger children, information on respiratory infections was provided, and mRNA vaccines were associated with a 3-fold increased risk of LRTI and a 2-fold
increased risk of RSV

Included were 246 259 pregnant women, of whom 34% received a first SARS-CoV-2 vaccination. Miscarriage occurred at a rate of 3.6 per 10 000 person-days among remotely vaccinated women and 3.2 per 10 000 person-days among those recently vaccinated, in contrast to a rate of 1.9 per 10 000 person-days among unvaccinated women, with corresponding aHR of 0.98 (95% confidence interval [CI] 0.91–1.07) and 1.00 (95% CI 0.93–1.08).